Search

Author/Creator Scheers, Ellen

1. Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. Issue 4 (11th December 2014)

Authors:
Devineni, Damayanthi; Murphy, Joseph; Wang, Shean‐Sheng; Stieltjes, Hans; Rothenberg, Paul; Scheers, Ellen; Mamidi, Rao N.V.S.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 4:Issue 4(2015:Jul./Aug.)
Page Start:
295
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. Issue 4 (11th December 2014)

Authors:
Devineni, Damayanthi; Murphy, Joseph; Wang, Shean‐Sheng; Stieltjes, Hans; Rothenberg, Paul; Scheers, Ellen; Mamidi, Rao N.V.S.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 4:Issue 4(2015:Jul./Aug.)
Page Start:
295
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. In vitro and physiologically‐based pharmacokinetic based assessment of drug–drug interaction potential of canagliflozin. (20th December 2016)

Authors:
Mamidi, Rao N. V. S.; Dallas, Shannon; Sensenhauser, Carlo; Lim, Heng Keang; Scheers, Ellen; Verboven, Peter; Cuyckens, Filip; Leclercq, Laurent; Evans, David C.; Kelley, Michael F.; Johnson, Mark D.; Snoeys, Jan
Journal:
British journal of clinical pharmacology
Issue:
Volume 83:Number 5(2017:May)
Page Start:
1082
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. (20th May 2015)

Authors:
Francke, Stephan; Mamidi, Rao N. V. S.; Solanki, Bhavna; Scheers, Ellen; Jadwin, Andrew; Favis, Reyna; Devineni, Damayanthi
Journal:
Journal of clinical pharmacology
Issue:
Volume 55:Number 9(2015:Sep.)
Page Start:
1061
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. (1st February 2021)

Authors:
Scheers, Ellen; Borgmans, Carine; Keung, Chi; Bohets, Hilde; Wynant, Inneke; Poggesi, Italo; Cuyckens, Filip; Leclercq, Laurent; Mamidi, Rao N. V. S.
Journal:
Xenobiotica
Issue:
Volume 51:Number 2(2021)
Page Start:
177
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib. (11th August 2021)

Authors:
De Zwart, Loeckie; Snoeys, Jan; Jacobs, Frank; Li, Lilian Y.; Poggesi, Italo; Verboven, Peter; Goris, Ivo; Scheers, Ellen; Wynant, Inneke; Monshouwer, Mario; Mamidi, Rao N. V. S.
Journal:
CPT: pharmacometrics & systems pharmacology
Issue:
Volume 10:Number 9(2021)
Page Start:
1107
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗